Search | Clinical Trials Finder

Conditions: Lung Transplant
Interventions: Emapalumab, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Hepatitis B
Interventions: IFN-γ 1b (Actimmune), Adefovir dipivoxil, IFN-γ 1b and Adefovir dipivoxil combination; Drug
Lead sponsor: Huntington Medical Research Institutes; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Itraconazole, Flucytosine, Fluconazole, Amphotericin B, Interferon gamma-1b; Drug
Lead sponsor: InterMune; Industry
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 7
States / cities: Birmingham, Alabama • St Louis, Missouri • Camden, New Jersey + 3 more

Conditions: Melanoma (Skin)
Interventions: MART-1 antigen, aldesleukin, gp100 antigen, recombinant CD40-ligand, recombinant interferon gamma, recombinant interleukin-4, sargramostim, therapeutic autologous dendritic cells, therapeutic tumor infiltrating lymphocytes, tyrosinase peptide, Candida albicans skin test reagent; Biological · Radiation
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Trifluridine; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Candidemia
Interventions: Interferon Gamma-1B; Drug
Lead sponsor: Radboud University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Colorectal Cancer
Interventions: 5-Fluorouracil, Leucovorin (LV), Gamma-Interferon-1b (IFN-γ), Bevacizumab; Drug
Lead sponsor: Accelerated Community Oncology Research Network; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Graft Versus Host Disease, Lymphoma
Interventions: aldesleukin, recombinant interferon gamma, busulfan, cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Friedreich Ataxia
Interventions: Interferon Gamma-1b; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Uveitis
Interventions: Interferon Gamma 1-b; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Interferon gamma-1b; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Hemophagocytic Lymphohistiocytoses
Interventions: Emapalumab-Lzsg; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anterior Uveitis, Uveitis
Interventions: Interferon Gamma-1b; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Solid Tumors
Interventions: interferon-gamma and nivolumab; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukocyte Adhesion Deficiency Syndrome
Interventions: Interferon gamma; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions: Autologous Monocytes + ACTIMMUNE + SYLATRON; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Interferon gamma-1b, Donor Leukocyte Infusion (DLI); Drug · Biological
Lead sponsor: Sawa Ito, MD; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: St Louis, Missouri • Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Sarcoidosis, SARS-CoV2 Infection, Vaccine Response Impaired
Interventions: Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation; Diagnostic Test
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
Interventions: Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, Epstein-Barr Virus Specific T-Lymphocytes; Biological
Lead sponsor: Jessie L. Alexander; Other
Eligibility: 1 Month to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Palo Alto, California

Conditions: Healthy, Mycobacterium Infections, Atypical
Interventions: interferon gamma; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Interferon-gamma 1b; Drug
Lead sponsor: InterMune; Industry
Eligibility: 20 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Pulmonary Fibrosis
Interventions: aerosol interferon-gamma; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Herpes Zoster, Allergy and Immunology, Corona Virus Infection
Interventions: SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline; Biological · Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 65 Years to 100 Years
Enrollment: 217 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Search by objective public record fields.

Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction

A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

Study of Gamma Interfereon in Metastatic Colorectal Carcinoma

Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

Interferon Gamma-1b in Friedreich Ataxia (FRDA)

The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma

The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH

Topical Interferon Gamma for Macular Edema Secondary to Uveitis

Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors

Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

Immune Response to SARS-CoV-2/COVID-19 Vaccination in Sarcoidosis

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma

A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents